CoQ10 / ubiquinol has 4 documented interactions in Magellan’s curated dataset, covering Anticoagulants (blood thinners), Chemotherapy and cancer therapy, Diabetes medications, Blood pressure medications. Each entry below gives the mechanism as the cited reference states it, the direction the risk runs, how serious that reference treats it, and what to actually do about it — which is, in every case, a conversation with the clinician or pharmacist who manages the prescription rather than a decision you make alone.
What it is. Coenzyme Q10 (CoQ10, ubiquinone) is a fat-soluble compound the body synthesizes and also obtains in small amounts from foods such as oily fish, organ meats, and nuts. Concentrated in the inner mitochondrial membrane, it serves as an essential electron-transport-chain cofactor for cellular ATP (energy) production and also functions as a lipid-soluble antioxidant.
Where it sits on the evidence. Magellan grades the supplement itself as Moderate evidence, with a typical studied dose of 100–400 mg/day (1,500 mg/day used in a multiple-system-atrophy trial). That grade is about whether it works, not about whether it is safe alongside your medication — the two questions are independent, and this page answers only the second.
Products this covers: Ubiquinol (Reduced CoQ10).
How the risks cluster. The entries split across 2 different mechanisms — opposing; additive — and they are not managed the same way, so read each one rather than assuming a single rule covers all of them.
Safety and efficacy are separate questions, and this page only answers the first. For the second, the study Magellan’s coverage of CoQ10 / ubiquinol rests on is:
“In a multicentre double-blind phase 2 RCT (n=139), high-dose ubiquinol (1,500 mg/day) slowed functional decline in multiple system atrophy (UMSARS part 2 difference -1.7 vs placebo) and was well tolerated.”
A strong result does not make a supplement safe alongside your prescription, and a documented interaction does not mean the supplement does not work. Magellan grades those two things separately, and neither grade moves for a commission.
Magellan’s Medication Safety Check runs entirely on your device — type the medicines you take and it flags every documented interaction in this dataset. Nothing you type is sent anywhere.
Open the Medication Safety Check →CoQ10 may make warfarin (Jantoven) less effective at thinning the blood, which could raise the risk of a dangerous blood clot; Mayo Clinic and NCCIH both flag this interaction.
Medicines in this group include: Warfarin (Coumadin, Jantoven), Apixaban (Eliquis), Rivaroxaban (Xarelto), Dabigatran (Pradaxa), Edoxaban (Savaysa), Heparin (Lovenox, Enoxaparin), Acenocoumarol (Sintrom).
NCCIH states CoQ10 may not be compatible with some types of cancer treatment, so people undergoing chemotherapy should discuss use with their oncology team before taking it.
Medicines in this group include: Methotrexate (Trexall, Otrexup), Tamoxifen (Nolvadex), Cisplatin, Doxorubicin (Adriamycin), Vincristine (Oncovin), Bortezomib (Velcade), Cyclophosphamide (Cytoxan).
NCCIH notes CoQ10 may interact with the diabetes drug insulin, which could affect blood sugar control.
Medicines in this group include: Metformin (Glucophage, Fortamet), Insulin (Humalog, Novolog), Glipizide (Glucotrol), Glyburide (Diabeta, Glynase), Glimepiride (Amaryl), Sitagliptin (Januvia), Empagliflozin (Jardiance), Dapagliflozin (Farxiga) and 5 more.
CoQ10 can itself lower blood pressure, so taking it with antihypertensive drugs may add to the blood-pressure-lowering effect.
Medicines in this group include: Amlodipine (Norvasc), Diltiazem (Cardizem, Tiazac), Verapamil (Calan, Verelan), Nifedipine (Procardia, Adalat), Hydrochlorothiazide (Hctz, Microzide), Chlorthalidone (Thalitone), Indapamide (Lozol), Furosemide (Lasix) and 6 more.
These are the warning signs that go with the medication classes on this page. They are general safety-netting, not a prediction that any supplement will cause them.
If something feels seriously wrong, do not wait for an appointment. Call 911 (US) or your local emergency number.
Severity describes the interaction as the cited reference frames it, not how a specific person will react. A “minor” entry in someone with kidney disease, on five other drugs, can matter more than a “major” one in someone on nothing else.
This is a curated set of interactions with citations — not an exhaustive pharmacology database. An interaction that is absent here has not been ruled out; it may simply not be documented in the references Magellan curates from. Supplements are also not batch-tested for identity or contamination the way prescription drugs are, so what is on the label is a claim rather than a guarantee. And most of these entries come from case reports and mechanistic work rather than randomized trials, which is exactly why the sensible response is a pharmacist review rather than either alarm or dismissal.
22 documented interactions across 17 supplements.
9 documented interactions across 9 supplements.
9 documented interactions across 9 supplements.
8 documented interactions · shares a drug class with CoQ10 / ubiquinol.
3 documented interactions · shares a drug class with CoQ10 / ubiquinol.
7 documented interactions · shares a drug class with CoQ10 / ubiquinol.
5 documented interactions · shares a drug class with CoQ10 / ubiquinol.
The mechanism and the research behind the compound itself.
A–Z of every supplement and drug class in this dataset, plus how to read an interaction.
What the research actually shows, graded independently of affiliate commissions.
Not without checking with the prescriber or pharmacist first. Magellan's dataset grades this as a major interaction: CoQ10 may make warfarin (Jantoven) less effective at thinning the blood, which could raise the risk of a dangerous blood clot; Mayo Clinic and NCCIH both flag this interaction. (Source: Coenzyme Q10 | NCCIH.)
4 interactions are documented in Magellan's curated dataset: 1 major, 2 moderate, 1 minor. They cover Anticoagulants (blood thinners), Chemotherapy and cancer therapy, Diabetes medications, Blood pressure medications. Absence from this list is not proof of safety — it means no interaction is documented in the references we curate from.
Magellan lists the typical studied dose as: 100–400 mg/day (1,500 mg/day used in a multiple-system-atrophy trial). Dose matters for interactions — several of the entries on this page describe effects that only appear at supplemental rather than dietary intakes.